Back in November 2017, the FDA announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies. Both draft guidance documents had 90-day comment periods, and we at LEAF joined forces with the Niskanen Center to submit comments to the FDA to ensure that the voice of the…

Not long ago, we wrote about some complications involving the WHO 13th programme of work. In the initial version of this document, developed by the WHO working group in November 2017, the problems of the elderly were nearly completely overlooked. The joint effort of our community helped to bring this critical flaw to public attention….

When it comes to healthcare, WHO remains the global flagship in terms of setting priorities and adjusting policies in the ever-changing landscape of healthcare needs. In the past few years, WHO has been making steps towards preparing our society to handle the “silver tsunami” and the increasing needs of the elderly population, which is expected…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD